Abstract Parkinson's disease (PD), the second most common progressive
neurodegenerative disease, develops and progresses for 10–15 years before the clinical …

Parkinson's disease (PD) is the most common neurodegenerative disorder with motor
symptoms. The neuropathological alterations characterizing the brain of patients with PD …

Antibodies against phosphorylated alpha-synuclein (aSyn) at S129 have emerged as the
primary tools to investigate, monitor, and quantify aSyn pathology in the brain and peripheral …

Objectives Detection of α‐synuclein aggregates by seed amplification is a promising
Parkinson disease biomarker assay. Understanding intraindividual relationships of α …

I read with interest the insightful article by Gonzalez-Ortiz et al. 1 regarding the development
of a new assay for quantification of phosphorylated threonine 217 tau (pT217-tau) in the …

A range of neurodegenerative disorders, collectively termed parkinsonian disorders, present
with a complex array of both motor and non-motor symptoms. Included in this group are …

Introduction Multiple system atrophy (MSA) is a rapidly progressive neurodegenerative
disorder characterized by the presence of glial cytoplasmic inclusions (GCIs) containing …

Alpha-synuclein (aSyn) within Lewy bodies, Lewy neurites, and other pathological hallmarks
of Parkinson's disease and synucleinopathies have consistently been shown to accumulate …

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by
motor symptoms such as tremors, rigidity, and bradykinesia, as well as non-motor symptoms …

Alpha-synuclein (aSyn) post-translational modifications (PTMs), particularly phosphorylation
at serine 129 and C-terminal truncations, are highly enriched in Lewy bodies (LBs), Lewy …